{
    "clinical_study": {
        "@rank": "40205", 
        "arm_group": [
            {
                "arm_group_label": "CC-223", 
                "arm_group_type": "Experimental", 
                "description": "CC-223 administration on study day 1 of Period 1 and study day 5 of Period 2"
            }, 
            {
                "arm_group_label": "Ketokonazole", 
                "arm_group_type": "Active Comparator", 
                "description": "Ketoconazole administration on study days 1 through 8 of Period 2"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a single-center open-label study to compare how CC-223 (the study drug being\n      investigated) interacts with the drug ketoconazole."
        }, 
        "brief_title": "CC-223 and Ketoconazole Drug-Drug Interaction Study", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "detailed_description": {
            "textblock": "This is a 2 period study, which lasts about 6 weeks long.  About 14 males will be entered\n      into the study, during which they will receive the study drug (a single dose of 20 mg\n      CC-223) 400 mg ketoconazole."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Must understand and voluntarily sign a written informed consent form before\n             participation.\n\n          2. Must be able to communicate with the study doctor, understand and comply with the\n             requirements of the study, and agree to adhere to restrictions and examination\n             schedules.\n\n          3. Healthy male subject of any race between 18 to 65 years of age, and in good health as\n             determined by a physical examination.\n\n             - For males: Agree to use barrier contraception not made of natural (animal) membrane\n             (for example, latex or polyurethane condoms are acceptable) when engaging in sexual\n             activity with a female of child-bearing potential while on study medication, and for\n             at least 28 days after the last dose of study medication.\n\n          4. Must have a body mass index between 18 and 33 kilograms/meter squared.\n\n          5. Clinical laboratory tests must be within normal limits or acceptable to the study\n             doctor.\n\n          6. Must not have a fever, with a blood pressure between 90/50 to 140/90 millimeters of\n             mercury, and pulse rate: between 40 to 110 beats per minute.\n\n          7. Must have a normal or clinically acceptable 12-lead electrocardiogram.\n\n        Exclusion Criteria:\n\n          1. History of any clinically significant and relevant neurological, gastrointestinal,\n             renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine,\n             hematological, allergic disease, drug allergies, or other major disorders.\n\n          2. Any condition which places the subject at unacceptable risk if he were to participate\n             in the study, or confounds the ability to interpret data from the study.\n\n          3. Used any prescribed or topical medication within one month before the first dose of\n             study drug, unless consultation between the sponsor and the study doctor.\n\n          4. Used any non-prescribed systemic or topical medication (including vitamin/mineral\n             supplements, and herbal medicines) within 2 weeks (30 days for St. John's Wort\u00ae) of\n             the first dose administration, unless sponsor agreement is obtained.\n\n          5. Has any surgical or medical conditions possibly affecting drug absorption,\n             distribution, metabolism and excretion of the study drug, for example, bariatric\n             procedure.\n\n          6. Donated blood or plasma within 2 months before the first dose of study drug.\n\n          7. History of drug abuse within 2 years before dosing, or a positive drug screening test\n             reflecting consumption of illicit drugs.\n\n          8. History of alcohol abuse within 2 years before dosing, or positive alcohol screen.\n\n          9. Known to have serum hepatitis or known to be a carrier of the hepatitis B surface\n             antigen, or hepatitis C antibody, or have a positive result to the test for Human\n             Immune virus antibodies at Screening.\n\n         10. Exposed to an investigational drug within one month 30 days before the first dose of\n             study drug.\n\n         11. Smoke more than 10 cigarettes per day, or the equivalent in other tobacco products."
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "14", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 8, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01896323", 
            "org_study_id": "CC-223-CP-003"
        }, 
        "intervention": [
            {
                "arm_group_label": "CC-223", 
                "description": "CC-223 20 mg tablets", 
                "intervention_name": "CC-223", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Ketokonazole", 
                "description": "Ketoconazole 400 mg tablets", 
                "intervention_name": "Ketoconazole", 
                "intervention_type": "Drug", 
                "other_name": "Nizoral"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Ketoconazole"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "April 3, 2014", 
        "number_of_arms": "2", 
        "official_title": "An Open-Label, Two-Period, Fixed-Sequence Study to Evaluate the Effect of Multiple Doses of Ketoconazole on the Single Dose Pharmacokinetics of CC-223 in Healthy Adult Male Subjects", 
        "overall_official": {
            "affiliation": "Celgene Corporation", 
            "last_name": "Edward O'Mara, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": [
                "Australia: Human Research Ethics Committee", 
                "Australia: National Health and Medical Research Council"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "AUC-area under the plasma concentration-time curve;", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours post dose"
            }, 
            {
                "description": "Cmax-maximum observed plasma concentration", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours post dose"
            }, 
            {
                "description": "Tmax - Time to maximum observed plasma concentration", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours post dose"
            }, 
            {
                "description": "t\u00bd - terminal elimination half-life in plasma", 
                "measure": "Pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "up to 96 hours post dose"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01896323"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of subjects with adverse events", 
            "measure": "Adverse Events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to  28 days after last dose of study drug"
        }, 
        "source": "Celgene Corporation", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Celgene Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}